Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study - Blackwell, K L; Burstein, H J; Storniolo, A M (J Clin Oncol, 2012)
et al.